<DOC>
	<DOCNO>NCT00111748</DOCNO>
	<brief_summary>The main goal study evaluate effectiveness combination drug , whether give safely together .</brief_summary>
	<brief_title>UARK 2005-01 Study Velcade , Thalidomide , Dexamethasone ( VTD ) With Without AdriamycinÂ® Relapsed/Refractory Patients</brief_title>
	<detailed_description>In study , two arm ( group ) . One arm receive Velcade , thalidomide , dexamethasone ( VTD ) , arm receive VTD Adriamycin . This study follow specific goal : To evaluate efficacy toxicity two treatment multiple myeloma patient , relapse least one course high-dose treatment autologous stem cell transplant , least two line conventional chemotherapy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients relapse multiple myeloma ( MM ) Patients must adequate platelet count &gt; 20,000 x 10^9/L , independent transfusion , unless due massive myeloma infiltration . Anticipated life expectancy least 3 month Ejection fraction echocardiogram ( ECHO ) multiple gated acquisition ( MUGA ) scan perform within 60 day prior registration ; leave ventricular ejection fraction ( LVEF ) &gt; 40 % ECHO MUGA . Female patient child bear age require negative pregnancy test indicate thalidomide safety guideline Patients must performance status 02 base Southwest Oncology Group ( SWOG ) criterion . Patients poor performance status ( 34 ) , base solely bone pain , eligible . All patient must inform investigational nature study must sign institutional review board ( IRB ) approve informed consent accordance institutional federal guideline . Evidence central nervous system ( CNS ) involvement Grade &gt; 2 peripheral neuropathy Hypersensitivity Velcade , boron , mannitol Recent ( &lt; 6 month ) myocardial infarction , cerebrovascular accident ( CVA ) /stroke , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrhythmia . Evidence chronic obstructive chronic restrictive pulmonary disease . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free least three year . Patients must significant comorbid medical condition uncontrolled life threaten infection . Pregnant nursing woman . Women childbearing potential must negative pregnancy test document within one week registration . Women men reproductive potential may participate unless agree use effective contraceptive method duration study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Myeloma</keyword>
</DOC>